title: New drug delivery nanosystem combining liposomal and dendrimeric technology (liposomal locked-in dendrimers) for cancer therapy.
abstract: Liposomal locked-in dendrimers (LLDs), the combination of liposomes and dendrimers in one formulation, represents a relatively new term in the drug carrier technology. LLDs undergone appropriate physicochemical investigation can merge the benefits of liposomal and dendrimeric nanocarriers. In this study generation 1 and 2 hydroxy-terminated dendrimers were synthesized and were then "locked" in liposomes consisting of DOPC/DPPG. The anticancer drug doxorubicin (Dox) was loaded into pure liposomes or LLDs and the final products were subjected to lyophilization. The loading of Dox as well as its in vitro release rate from all systems was determined and the interaction of liposomes with dendrimers was assessed by thermal analysis and fluorescence spectroscopy. The results were very promising in terms of drug encapsulation and release rate, factors that can alter the therapeutic profile of a drug with low therapeutic index such as Dox. Physicochemical methods revealed a strong, generation dependent, interaction between liposomes and dendrimers that probably is the basis for the higher loading and slower drug release from the LLDs comparing to pure liposomes.
authors.affiliation: National Hellenic Research Foundation (NHRF), Institute of Organic and Pharmaceutical Chemistry, Athens, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Gardikis
authors.forename: Sophia
authors.initials: S
authors.lastname: Hatziantoniou
authors.forename: Madalina
authors.initials: M
authors.lastname: Bucos
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Fessas
authors.forename: Marco
authors.initials: M
authors.lastname: Signorelli
authors.forename: Theodoros
authors.initials: T
authors.lastname: Felekis
authors.forename: Maria
authors.initials: M
authors.lastname: Zervou
authors.forename: Constantinos G
authors.initials: CG
authors.lastname: Screttas
authors.forename: Barry R
authors.initials: BR
authors.lastname: Steele
authors.forename: Maksim
authors.initials: M
authors.lastname: Ionov
authors.forename: Maria
authors.initials: M
authors.lastname: Micha-Screttas
authors.forename: Barbara
authors.initials: B
authors.lastname: Klajnert
authors.forename: Maria
authors.initials: M
authors.lastname: Bryszewska
authors.forename: Costas
authors.initials: C
authors.lastname: Demetzos
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry; D050091:Dendrimers / Q000737:chemistry*; D004055:Differential Thermal Analysis; D004317:Doxorubicin / Q000008:administration & dosage / Q000737:chemistry; D004337:Drug Carriers; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005612:Freeze Drying; D007202:Indicators and Reagents; D008081:Liposomes / Q000737:chemistry*; D008560:Membrane Fluidity; D009369:Neoplasms / Q000188:drug therapy*; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; D012995:Solubility; D013050:Spectrometry, Fluorescence
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D050091:Dendrimers; D004337:Drug Carriers; D007202:Indicators and Reagents; D008081:Liposomes; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; D004317:Doxorubicin; C017251:1,2-oleoylphosphatidylcholine; C030345:1,2-dipalmitoylphosphatidylglycerol